Matthew Guo

Mr. Matthew Guo

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2023 in Clinical Lung Cancer
Verified
Journal Article
Closed access
MGMatthew Guo
Matthew Guo
ABAanika Balaji
Aanika Balaji
JMJoseph C Murray
Joseph C Murray
JRJoshua E Reuss
Joshua E Reuss
SSSeema Mehta Steinke
Seema Mehta Steinke
JNJarushka Naidoo
Jarushka Naidoo

23 May 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
PAParul Agarwal
Parul Agarwal
MGMatthew Guo
Matthew Guo
KMKabeer Munjal
Kabeer Munjal
HQHanfei Qi
Hanfei Qi
RPRose Parkinson
Rose Parkinson
AOArsen Osipov
Arsen Osipov
Purpose: Borderline resectable pancreatic ductal adenocarcinoma (PDAC) is treated with perioperative chemotherapy and surgical resection with or without stereotactic body radiotherapy (SBRT), but long-term survival is rare. GVAX is a GM-CSF–secreting vaccine that activates T-cell immunity against tumor-associated antigens. This multicenter phase II clinical trial evaluated the safety and immune effects of GVAX/cyclophosphamide/nivolumab and SBRT on the PDAC tumor microenvironment (TME). Patients and Methods: Patients received neoadjuvant mFOLFIRINOX or gemcitabine/nab-paclitaxel if intolerant to mFOLFIRINOX followed by combination immunotherapy and SBRT before surgical resection. The primary endpoint was CD8+ T-cell density in surgical specimens compared with in historic control samples treated with neoadjuvant mFOLFIRINOX and SBRT only. Pathologic response rate, overall survival, and exploratory immune evaluation of the TME are also reported. Results: Thirty-one patients were enrolled from January 2018 to July 2021. Eighteen patients received at least one dose of combined immunotherapy. Fourteen patients underwent definitive surgical resection, and one pathologic complete response was observed. At a median follow-up of 19.5 months, the median overall survival was 20.4 months (95% confidence interval, 18.2–not achieved). There was no difference in the mean CD8 T-cell density between study patients and historic control patients. Nonsignificant increases in the abundance score for specific immune cell subsets were observed in responders as compared with nonresponders. Conclusions: The addition of combined immunotherapy and SBRT was safe and feasible in this patient population. No difference was observed in the mean CD8 T-cell density between study patients and historic controls. These findings support the need for better characterization of how neoadjuvant immunotherapy may shift the phenotype of the PDAC TME.

8 August 2022 in Clinical Lung Cancer
Verified
Journal Article
Open access
MGMatthew Guo
Matthew Guo
JMJoseph C. Murray
Joseph C. Murray
PGPaola Ghanem
Paola Ghanem
KVK Ranh Voong
K Ranh Voong
RHRussell K. Hales
Russell K. Hales
KMKristen A. Marrone
Kristen A. Marrone
Consolidation durvalumab immunotherapy following definitive chemoradiation (CRT) for unresectable stage III non-small cell lung cancer (NSCLC) improves overall survival. As therapeutic options for patients with KRAS-driven disease evolve, more understanding regarding genomic determinants of response and patterns of progression for durvalumab consolidation is needed to optimize outcomes. We conducted a single-institutional retrospective analysis of real-world patients with locally advanced, unresectable NSCLC who completed CRT and received durvalumab consolidation. Kaplan-Meier analyses compared progression-free survival (PFS) and overall survival (OS) from start of durvalumab consolidation between patients with KRAS-mutated and non-mutated tumors. Fisher's exact test was used to compare rates of intrathoracic or extrathoracic progression. Of 74 response-evaluable patients, 39 had clinical genomic profiling performed. 18 patients had tumors with KRAS mutations, 7 patients had tumors with non-KRAS actionable alterations (EGFR, ALK, ERBB2, BRAF, MET, RET, or ROS1), and 14 patients had tumors without actionable alterations. Median PFS for the overall cohort was 16.1 months. PFS for patients with KRAS-mutated NSCLC was 12.6 months versus 12.7 months for patients with non-actionable tumors (P= 0.77, log-rank). Fisher's exact test revealed a statistically significantly higher rate of extrathoracic progression versus intrathoracic-only progression for patients with KRAS-driven disease compared to patients with non-actionable tumors (P= 0.015). Patients with KRAS-mutated NSCLC derived similar benefit from durvalumab as patients with non-actionable tumors. A higher rate of extrathoracic progression was also observed among the patients with KRAS-mutated NSCLC compared to patients with non-actionable tumors. This highlights the potential unmet needs for novel systemic therapies and surveillance methods for KRAS-mutated stage III NSCLC.

8 February 2022 in eLife
Verified
Journal Article
Open access
CPCatalina Pereira
Catalina Pereira
GAGerardo A Arroyo-Martinez
Gerardo A Arroyo-Martinez
MGMatthew Guo
Matthew Guo
MDMichael S Downey
Michael S Downey
EKEmma R Kelly
Emma R Kelly
RWRobert Weiss
Robert Weiss
DNA damage response mechanisms have meiotic roles that ensure successful gamete formation. While completion of meiotic double-strand break (DSB) repair requires the canonical RAD9A-RAD1-HUS1 (9A-1-1) complex, mammalian meiocytes also express RAD9A and HUS1 paralogs, RAD9B and HUS1B, predicted to form alternative 9-1-1 complexes. The RAD1 subunit is shared by all predicted 9-1-1 complexes and localizes to meiotic chromosomes even in the absence of HUS1 and RAD9A. Here, we report that testis-specific disruption of RAD1 in mice resulted in impaired DSB repair, germ cell depletion, and infertility. Unlike Hus1 or Rad9a disruption, Rad1 loss in meiocytes also caused severe defects in homolog synapsis, impaired phosphorylation of ATR targets such as H2AX, CHK1, and HORMAD2, and compromised meiotic sex chromosome inactivation. Together, these results establish critical roles for both canonical and alternative 9-1-1 complexes in meiotic ATR activation and successful prophase I completion.

23 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
ALAmanda Loehr
Amanda Loehr
TPTimothy M. Pierpont
Timothy M. Pierpont
EGEric Gelsleichter
Eric Gelsleichter
AGAnabella Maria Galang
Anabella Maria Galang
IFIrma Fernandez
Irma Fernandez
RWRobert Weiss
Robert Weiss
Testicular germ cell tumors (TGCTs) are exceptionally sensitive to genotoxic chemotherapy, resulting in a high cure rate for the young men presenting with these malignancies. However, this treatment is associated with significant toxicity, and a subset of malignant TGCTs demonstrate chemoresistance. Mixed nonseminomas often contain pluripotent embryonal carcinoma (EC) cells, the cancer stem cells (CSCs) of these tumors. We hypothesized that differentiation therapy, a treatment strategy which aims to induce differentiation of tumor-propagating CSCs to slow tumor growth, could effectively treat mixed nonseminomas without significant toxicity. The FDA-approved antipsychotic thioridazine and the agricultural antibiotic salinomycin are two drugs previously found to selectively target CSCs, and here we report that these agents differentiate EC cells in vitro and greatly reduce their tumorigenic potential in vivo. Using a novel transformed induced pluripotent stem cell allograft model and a human xenograft model, we show that thioridazine extends the survival of tumor-bearing mice and can reduce the number of pluripotent EC cells within tumors. These results suggest that thioridazine could be repurposed as an alternative TGCT treatment that avoids the toxicity of conventional chemotherapeutics.

26 August 2026 in Cancer Discovery
Verified
Journal Article
Closed access
SHS. Daniel Haldar
S. Daniel Haldar
AHAmanda L. Huff
Amanda L. Huff
HWHejia Henry Wang
Hejia Henry Wang
ZZZirui Zhu
Zirui Zhu
MBMaureen Berg
Maureen Berg
NZNeeha Zaidi
Neeha Zaidi
Pancreatic ductal adenocarcinoma (PDAC) arises from precursor lesions over a decade-plus, offering a window for interception in high-risk individuals, but current surveillance detects a minority of precursors. Mutant KRAS (mKRAS) is present in most PDACs and their precursors, making it an appealing target for immune-based interception. We conducted a phase I, first-in-human study of a peptide vaccine targeting 6 common KRAS mutations (mKRAS-VAX) in 20 individuals with hereditary PDAC predisposition and a radiographic pancreatic abnormality (NCT05013216) to assess safety, immunogenicity, and T-cell persistence. Adverse events were grade 1 to 2. Vaccination elicited a significant mKRAS-specific T-cell response in 18 of 20 (90%) participants. Longitudinal T-cell receptor sequencing demonstrated persistence of vaccine-induced mKRAS-specific clonotypes for up to 2 years. Over a median follow-up of 16.5 months, no participants developed PDAC. These findings demonstrate that mKRAS-VAX is safe and generates durable T-cell responses, which support the advancement of mKRAS-targeted vaccination for PDAC interception. Significance: In high-risk individuals with hereditary predisposition to PDAC, a first-in-human peptide vaccine targeting mKRAS (mKRAS-VAX) was safe and elicited durable T-cell responses, supporting further development of mKRAS-targeted vaccination for immune interception for pancreatic precancers.